Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Brokerages

Maze Therapeutics, Inc. (NASDAQ:MAZE) has been assigned an average rating of “Buy” from the eleven research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $41.8750.

A number of research firms recently commented on MAZE. HC Wainwright increased their price target on Maze Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday. Guggenheim increased their target price on Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a report on Monday, September 15th. Wedbush raised their target price on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Raymond James Financial assumed coverage on Maze Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price target for the company. Finally, Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th.

Insider Activity at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its holdings in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the period. Russell Investments Group Ltd. raised its position in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after acquiring an additional 1,725 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Maze Therapeutics in the 3rd quarter valued at $52,000. CWM LLC acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at $28,000. Finally, Legal & General Group Plc boosted its position in shares of Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after purchasing an additional 3,371 shares during the last quarter.

Maze Therapeutics Stock Up 2.7%

Shares of Maze Therapeutics stock opened at $42.60 on Friday. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $43.29. The stock has a market capitalization of $2.05 billion and a P/E ratio of -2.04. The company has a 50-day simple moving average of $31.67 and a 200 day simple moving average of $20.68.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.